• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

In­di­v­ior ax­es schiz­o­phre­nia drug and shrinks rev­enue guid­ance

10 months ago
R&D
Pharma

Two health­care SPACs go pub­lic, with sev­er­al more on the hunt for deals

10 months ago
Financing
Deals

How SCO­TUS' de­ci­sion in Chevron could change the way the FDA reg­u­lates bio­phar­ma

10 months ago
FDA+
Law

Metageno­mi sci­ence chief de­parts, just a few months af­ter IPO

10 months ago
People
Startups

Ideaya rais­es $302M; Ab­b­Vie to seek ap­proval in gi­ant cell ar­teri­tis

10 months ago
News Briefing

Spin­outs, pen­sion re­forms and a GSK vet in cab­i­net: What the new UK gov­ern­ment could mean for life sci­ences

10 months ago
Financing
Startups

Im­mutep’s LAG-3 drug scores in Phase 2b head and neck can­cer test

10 months ago
R&D

Mikael Dol­sten isn’t the on­ly one mov­ing on from Pfiz­er; Lil­ly names in­ter­im fi­nance chief

10 months ago
People
Peer Review

Roche's gene ther­a­py biotech Spark is lay­ing off em­ploy­ees, end­ing some ear­ly-stage pro­grams

11 months ago
People
Cell/Gene Tx

Ab­b­Vie asks Supreme Court to re­con­sid­er rul­ing on at­tor­ney-client com­mu­ni­ca­tion

11 months ago
Pharma
Law

Sen­ate unan­i­mous­ly pass­es bi­par­ti­san phar­ma patent bill

11 months ago
Pharma
FDA+

Ab­b­Vie's Hu­mi­ra is still on top, but biosim­i­lars are chip­ping away at its dom­i­nance

11 months ago
Pharma

Il­lu­mi­na com­peti­tor El­e­ment Bio­sciences rais­es $277M in Se­ries D

11 months ago
Financing
Diagnostics

J&J and Emer­gent set­tle Covid con­tract dis­pute; Siegfried names new CEO

11 months ago
Manufacturing

Faron de­tails clin­i­cal plans for MDS drug; Cara to seek 's­trate­gic' op­tions

11 months ago
News Briefing

JPM’s life sci­ences VC team is grow­ing

11 months ago
People

Fund­ing for biotech star­tups had its best quar­ter in two years — sort of

11 months ago
Financing

Ten biotech ex­ec­u­tives who reaped the biggest M&A wind­falls, net­ting $40M+ ex­it pack­ages

11 months ago
People
Deals

Pfiz­er press­es for­ward with once-dai­ly GLP-1 pill in long-await­ed move

11 months ago
R&D
Pharma

Ipsen takes on an­oth­er ADC, this time from a Chi­na-based biotech

11 months ago
Deals
R&D

FDA re­jects No­vo Nordisk’s once-week­ly in­sulin af­ter ques­tion­ing risks

11 months ago
FDA+
Manufacturing

No­var­tis to shut down San Diego tech­ni­cal re­search and de­vel­op­ment fa­cil­i­ty

11 months ago
People

Al­most all pa­tients quit weight loss shots with­in two years, analy­sis finds

11 months ago
Pharma
Health Tech

No­vo-part­nered 3D bio­print­ing biotech gets $70M+ from Cana­di­an gov­ern­ment

11 months ago
Financing
Manufacturing
First page Previous page 132133134135136137138 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times